TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency

What is the purpose of this trial?

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib.


Participation Guidelines

Ages: 18 years and younger

Gender: Male only


Clovis Oncology, Inc.

Start Date: 11/17/2017

End Date: 10/31/2019

Last Updated: 02/22/2018

Study HIC#: 2000020433